Outcome Research to Confirm the Anti-anginal Effect of T89 in Patients With Stable Angina
Status:
Recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, double-blind, randomized, placebo-controlled, parallel-group phase 3
clinical study to confirm the safety and efficacy of T89 in patients with stable angina
pectoris, with an extended open-label period to evaluate the long-term safety of T89. This
study includes three main periods: the first study period is a 3-week single-blind qualifying
run-in period to screen eligible stable angina patients by exercise tolerance test (ETT). The
second study period is a 8-week double-blind treatment period to evaluate the efficacy and
safety of T89 in patients with stable angina by ETT. And, the last study period is a 44-week
open-label period to observe long-term use safety of T89.